Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | CASR | P41180 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11454087 | 0.85 | HTR1A (0.63) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL15677583 | 0.84 | HTR1A (0.66) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL10488463 | 0.82 | ADRB1 (0.64) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL10203042 | 0.81 | HTR1A (0.63) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL6222800 | 0.81 | HTR1A (0.55) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL11803062 | 0.80 | ADRB1 (0.72) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL8531327 | 0.80 | HTR1A (0.57) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL6456134 | 0.80 | HTR1A (0.61) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL27736563 | 0.80 | HTR1A (0.61) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL772630 | 0.79 | NOS2 (0.48) | HTR1AADRA2AADRA2BMAOAHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010014263-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ARCA DISCOVERY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| EP-0741705-A1 | 4-(2-(3-ARYLOXY-2-HYDROXYPROPYLAMINO ALKYLOXY)-5-NITROPHENYL)-1,4-DIHYDROPYRIDINES AS ANTIHYPERTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020576-A1 | 4-(2-(3-ARYLOXY-2-HYDROXYPROPYLAMINO ALKYLOXY)-5-NITROPHENYL)-1,4-DIHYDROPYRIDINES AS ANTIHYPERTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-03 | — | — | WO | disclosed |
| WO-1994002463-A1 | ANTIHYPERTENSIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-03 | — | — | WO | disclosed |
| US-5051446-A | Cardiovascular disorders | E. I. DU PONT DE NEMOURS & CO. (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0194752-A1 | Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-17 | — | — | EP | disclosed |
| WO-1986004581-A1 | DIHYDROPYRIDINE ALKANOLAMINES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-08-14 | — | — | WO | disclosed |
| EP-0041492-B1 | NEW SUBSTITUTED 3-PHENOXY-1-ALKOXYCARBONYL-ALKYLAMINO-PROPANOL-2-S HAVING BETA RECEPTOR BLOCKING PROPERTIES | Aktiebolaget Hässle (SE) | 1985-03-20 | — | — | EP | disclosed |
| EP-0041492-A1 | New substituted 3-phenoxy-1-alkoxycarbonyl-alkylamino-propanol-2-s having beta receptor blocking properties | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | disclosed |
| US-4025646-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3959338-A | BETA-ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE | BOEHRINGER INGELHEIM GMBH | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HTR1A 3503/4885ADRA2A 4058/4885ADRA2B 4185/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HTR1A 3503/4885ADRA2A 4058/4885ADRA2B 4185/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | HTR1A 3503/4885ADRA2A 4058/4885ADRA2B 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.